For years Alkermes Inc. has been developing extended-release formulations of drugs using its Medisorb technology. The company now is shifting much of that work to its new LinkeRx technology, a next-generation formulation technology for extended-release injectable drugs.
The technology employs the molecular modification of drug compounds, which Alkermes believes will reduce both manufacturing costs and complications encountered by microsphere encapsulation.
Initially, Alkermes will use LinkeRx to develop extended-release formulations of CNS drugs.
Medisorb works by encapsulating the drug molecule in a biodegradable polymer microsphere. The